191 related articles for article (PubMed ID: 31981279)
21. Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results.
Başar O; Yimaz B; Ekiz F; Giniş Z; Altinbaş A; Aktaş B; Tuna Y; Çoban S; Delibaş N; Yüksel O
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):152-8. PubMed ID: 23391746
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic accuracy of APRI and FIB-4 for predicting hepatitis B virus-related liver fibrosis accompanied with hepatocellular carcinoma.
Xiao G; Zhu F; Wang M; Zhang H; Ye D; Yang J; Jiang L; Liu C; Yan L; Qin R
Dig Liver Dis; 2016 Oct; 48(10):1220-6. PubMed ID: 27599803
[TBL] [Abstract][Full Text] [Related]
23. The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.
Li Q; Lu C; Li W; Huang Y; Chen L
Oncotarget; 2017 Apr; 8(17):28641-28649. PubMed ID: 28415736
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT ≤ 2 ULN: A retrospective cohort study.
Li Q; Ren X; Lu C; Li W; Huang Y; Chen L
Medicine (Baltimore); 2017 Mar; 96(12):e6336. PubMed ID: 28328813
[TBL] [Abstract][Full Text] [Related]
25. Performance of simple noninvasive scoring systems for the prediction of advanced fibrosis in patients with chronic hepatitis B.
Lang S; Kütting F; Staub A; Schramowski J; Schramm C; Kasper P; Goeser T; Steffen HM; Demir M
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1235-1240. PubMed ID: 28885276
[TBL] [Abstract][Full Text] [Related]
26. Non-invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta.
Kalkan Ç; Yılmaz Y; Erdoğan BD; Savaş B; Yurdcu E; Çalışkan A; Keskin O; Gencdal G; Zeybel M; Törüner M; Bozdayi AM; Idilman R; Yurdaydin C
J Viral Hepat; 2023 May; 30(5):406-416. PubMed ID: 36651603
[TBL] [Abstract][Full Text] [Related]
27. How effective are APRI, FIB-4, FIB-5 scores in predicting liver fibrosis in chronic hepatitis B patients?
Sapmaz FP; Büyükturan G; Sakin YS; Kalkan İH; Atasoy P
Medicine (Baltimore); 2022 Sep; 101(36):e30488. PubMed ID: 36086763
[TBL] [Abstract][Full Text] [Related]
28. Red cell distribution width to platelet ratio predicts liver fibrosis in patients with autoimmune hepatitis.
Wang H; Wang J; Xia J; Yan X; Feng Y; Li L; Chen J; Liu D; Ding W; Yang Y; Huang R; Wu C
Medicine (Baltimore); 2020 Aug; 99(34):e21408. PubMed ID: 32846758
[TBL] [Abstract][Full Text] [Related]
29. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
[TBL] [Abstract][Full Text] [Related]
30. Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy.
Kim MN; Lee JH; Chon YE; Ha Y; Hwang SG
Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):433-439. PubMed ID: 31490417
[TBL] [Abstract][Full Text] [Related]
31. Optimized cutoffs of gamma-glutamyl transpeptidase-to-platelet ratio, aspartate aminotransferase-to-platelet ratio index, and fibrosis-4 scoring systems for exclusion of cirrhosis in patients with chronic hepatitis B.
Liu X; Li H; Wei L; Tang Q; Hu P
Hepatol Commun; 2022 Jul; 6(7):1664-1672. PubMed ID: 35312182
[TBL] [Abstract][Full Text] [Related]
32. A novel non-invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD.
Wang J; Huang R; Liu J; Lai R; Liu Y; Zhu C; Qiu Y; He Z; Yin S; Chen Y; Yan X; Ding W; Zheng Q; Li J; Wu C
J Viral Hepat; 2023 Apr; 30(4):287-296. PubMed ID: 36696366
[TBL] [Abstract][Full Text] [Related]
33. Development of a model based on biochemical, real‑time tissue elastography and ultrasound data for the staging of liver fibrosis and cirrhosis in patients with chronic hepatitis B.
Xu SH; Li Q; Hu YP; Ying L
Mol Med Rep; 2016 Oct; 14(4):3609-19. PubMed ID: 27573619
[TBL] [Abstract][Full Text] [Related]
34. Serum N-glycan markers for diagnosing liver fibrosis induced by hepatitis B virus.
Cao X; Shang QH; Chi XL; Zhang W; Xiao HM; Sun MM; Chen G; An Y; Lv CL; Wang L; Nan YM; Chen CY; Tan ZN; Liu XE; Zhuang H
World J Gastroenterol; 2020 Mar; 26(10):1067-1079. PubMed ID: 32205997
[TBL] [Abstract][Full Text] [Related]
35. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients.
Karagoz E; Ulcay A; Tanoglu A; Kara M; Turhan V; Erdem H; Oncul O; Gorenek L
Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1320-4. PubMed ID: 25210777
[TBL] [Abstract][Full Text] [Related]
36. A Novel Noninvasive Program for Staging Liver Fibrosis in Untreated Patients With Chronic Hepatitis B.
Chen Y; Wang Y; Chen Y; Yu Z; Chi X; Hu KQ; Li Q; Tan L; Xiang D; Shang Q; Lei C; Chen L; Hu X; Wang J; Liu H; Lu W; Chi W; Dong Z; Wang X; Li Z; Xiao H; Chen D; Bai W; Zhang C; Xiao G; Qi X; Chen J; Zhou L; Sun H; Deng M; Qi X; Zhang Z; Qi X; Yang Y
Clin Transl Gastroenterol; 2019 May; 10(5):1-12. PubMed ID: 31033506
[TBL] [Abstract][Full Text] [Related]
37. Value of gamma-glutamyltranspeptidase-to-platelet ratio in diagnosis of hepatic fibrosis in patients with chronic hepatitis B.
Hu YC; Liu H; Liu XY; Ma LN; Guan YH; Luo X; Ding XC
World J Gastroenterol; 2017 Nov; 23(41):7425-7432. PubMed ID: 29151696
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic accuracy of transient elastography (FibroScan) versus the aspartate transaminase to platelet ratio index in assessing liver fibrosis in chronic hepatitis B: the role in primary care setting.
Lesmana CR; Salim S; Hasan I; Sulaiman AS; Gani RA; Pakasi LS; Lesmana LA; Krisnuhoni E; Budihusodo U
J Clin Pathol; 2011 Oct; 64(10):916-20. PubMed ID: 21670074
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of a potential biomarker to improve the assessment of liver fibrosis progression in patients with chronic hepatitis B.
Chen J; Yu S; Lang Z; Jin Y; Zhou G; Tao Q; Wang X; Zheng J
J Med Virol; 2023 Jan; 95(1):e28239. PubMed ID: 36258661
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection.
Li Q; Lu C; Li W; Huang Y; Chen L
Sci Rep; 2017 Jul; 7(1):5429. PubMed ID: 28710435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
